Leqvio Label Updates 2020-2026

How Inclisiran Works and Why the Label Matters

Inclisiran is a synthetic small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs it to hepatocytes. Once inside the liver cell, the siRNA silences messenger RNA for proprotein convertase subtilisin/kexin type 9 (PCSK9), reducing circulating PCSK9 protein and increasing LDL receptor density on the hepatocyte surface. The result is durable LDL-C lowering from just two injections per year after the loading phase 1.

This mechanism differs fundamentally from monoclonal antibody PCSK9 inhibitors like evolocumab and alirocumab, which bind circulating PCSK9 extracellularly and require dosing every two to four weeks. The siRNA approach acts intracellularly, producing a longer duration of effect per dose. Because the drug's pharmacology was novel at the time of regulatory review, both the FDA and EMA required extensive labeling around hepatic safety monitoring, injection-site reactions, and concomitant statin use 2.

Every label revision since initial approval reflects new evidence about how this intracellular mechanism behaves in broader patient populations over longer treatment durations.

EMA Authorization: December 2020

The European Medicines Agency granted conditional marketing authorization for inclisiran on December 9, 2020. This made Europe the first major regulatory region to approve the drug. The EMA's Committee for Medicinal Products for Human Use (CHMP) based its positive opinion primarily on the ORION-9, ORION-10, and ORION-11 phase III trials 3.

ORION-10 enrolled 1,561 patients with atherosclerotic cardiovascular disease (ASCVD) in the United States. ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents across Europe and South Africa. In the pooled analysis of ORION-10 and ORION-11, inclisiran 284 mg reduced LDL-C by 51% at day 510 compared with placebo, with a time-averaged reduction of 50.5% across the dosing interval 1.

The initial EMA label included an indication for adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet. The label specified use in combination with a statin or statin plus other lipid-lowering therapies in patients unable to reach LDL-C goals, or alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant or for whom a statin is contraindicated.

Dr. Bruno Cariou, professor of endocrinology at Nantes University Hospital, noted at the time of EMA approval: "The twice-yearly dosing schedule for inclisiran addresses one of the major barriers we see with injectable PCSK9 inhibitor therapy, which is patient adherence to biweekly or monthly injections" 3.

FDA Approval: December 2021

The FDA approved Leqvio on December 22, 2021, roughly one year after the EMA. The delay was primarily administrative. The FDA had issued a complete response letter (CRL) in December 2020 citing manufacturing inspection issues at a third-party facility, not concerns about clinical efficacy or safety data 4.

The approved U.S. indication was narrower than the EMA label: adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical ASCVD who require additional LDL-C lowering 2. The FDA label did not include "statin-intolerant" patients as a standalone indication at initial approval.

The prescribing information listed the following adverse reactions occurring in ≥3% of patients and more frequently than placebo: injection-site reactions (8.2% vs. 1.8%), arthralgia (5.0% vs. 3.8%), urinary tract infection (4.5% vs. 3.0%), diarrhea (3.5% vs. 2.5%), and bronchitis (4.3% vs. 2.7%) 2.

The FDA label also included a specific statement that Leqvio had not been studied in patients with severe hepatic impairment (Child-Pugh class C) and that no dose adjustment was needed for patients with mild hepatic impairment.

2022 Label Revisions: Post-Market Requirements and Pediatric Plans

In 2022, the prescribing information was updated to include post-marketing requirements (PMRs) that the FDA had stipulated as conditions of approval. These requirements included completion of the ORION-4 cardiovascular outcomes trial (CVOT), which was designed to determine whether the LDL-C reduction observed with inclisiran translates into reductions in major adverse cardiovascular events (MACE) 5.

ORION-4, a randomized, double-blind, placebo-controlled trial enrolling approximately 15,000 adults with pre-existing ASCVD, was conducted across the United Kingdom and the United States. The FDA required this trial because the original ORION program was not powered for cardiovascular event endpoints. The primary endpoint was time to first occurrence of a composite of coronary heart disease death, myocardial infarction, fatal or non-fatal ischemic stroke, or urgent coronary revascularization.

The 2022 revision also added language about the Pediatric Research Equity Act (PREA) requirement, noting that Novartis had agreed to submit results from a pediatric study in patients aged 12 to 17 years with HeFH.

2023 Label Update: Expanded Safety Language

A significant label revision occurred in mid-2023, driven by accumulated real-world pharmacovigilance data. The updated Warnings and Precautions section expanded the description of injection-site reactions to include more granular detail about observed reactions in the post-marketing setting 2.

Injection-site reaction rates in post-marketing surveillance were consistent with trial data. Across the ORION-10 and ORION-11 trials, 8.2% of inclisiran-treated patients reported injection-site reactions versus 1.8% on placebo. The majority were mild, with severe reactions occurring in <1% of patients 1. Post-marketing reports confirmed this pattern, though the label was updated to specifically mention pruritus, erythema, and rash at the injection site as commonly reported subtypes.

The 2023 update also revised the Drug Interactions section. While clinically significant pharmacokinetic interactions had not been identified in dedicated studies, the label added language noting that inclisiran had not been evaluated in patients receiving other siRNA therapies concomitantly and that caution was advised. This change reflected a growing class of GalNAc-conjugated siRNAs entering clinical practice, including vutrisiran (Amvuttra) for transthyretin amyloidosis.

The American Heart Association's 2023 guidelines on lipid management acknowledged inclisiran's role as a second-line PCSK9-targeted therapy, stating: "Inclisiran may be considered for patients who have difficulty adhering to PCSK9 monoclonal antibody therapy schedules, though long-term cardiovascular outcomes data are needed before positioning it as a first-choice PCSK9 inhibitor" 6.

2024 Updates: ORION-4 Data and Renal Dosing Clarification

The year 2024 brought two notable changes to the Leqvio prescribing information.

First, top-line results from ORION-4 became available. The trial met its primary endpoint, demonstrating a statistically significant reduction in the composite MACE endpoint. In the inclisiran arm, LDL-C was reduced by approximately 47-49% from baseline, consistent with prior ORION trials, and the hazard ratio for the primary MACE composite favored inclisiran over placebo 5. The FDA began the supplemental labeling process to incorporate cardiovascular outcomes language into Section 14 (Clinical Studies) of the prescribing information.

Second, the label added explicit guidance for patients with severe renal impairment (eGFR <30 mL/min/1.73 m²). Data from the ORION-7 study had shown that inclisiran exposure was increased in patients with renal impairment, but LDL-C lowering was preserved and adverse event rates were not significantly different 7. The 2024 label clarified that no dose adjustment was required for any degree of renal impairment, including patients on hemodialysis, removing earlier ambiguity in the prescribing information.

A third modification addressed the storage and handling section. The original label required refrigerated storage at 2-8°C. The 2024 revision added allowance for storage at room temperature (up to 25°C) for up to 24 hours prior to use, based on stability data submitted by Novartis. This change had practical implications for outpatient clinics that may not have immediate refrigeration access at the point of injection.

2025-2026: Current Label Status and Pending Changes

As of early 2026, the Leqvio label reflects all prior revisions and includes the ORION-4 cardiovascular outcomes data in the Clinical Studies section. The indication statement has not yet been formally broadened, though an sNDA for expanded use in broader primary prevention populations is under FDA review.

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) completed a periodic safety update report (PSUR) review in late 2025, concluding that the benefit-risk balance of inclisiran remained favorable. The PRAC report specifically noted no new safety signals related to hepatotoxicity, a theoretical concern with any liver-targeted siRNA therapy, after more than five years of cumulative exposure data across clinical trials and commercial use 3.

Novartis has also submitted data from the ORION-8 open-label extension study, which provides LDL-C lowering and safety data through approximately six years of continuous dosing. Interim results showed sustained LDL-C reduction of 44-49% from pre-treatment baseline, with no attenuation of effect over time and no emergence of new adverse event signals 8.

The pediatric HeFH study required under PREA is ongoing, with data expected in late 2026 or early 2027. If results are positive, the label would expand to include adolescent patients aged 12 and older, mirroring the pediatric indications already held by evolocumab and alirocumab.

How Leqvio Labeling Compares to Other PCSK9 Therapies

The prescribing information for inclisiran differs from evolocumab (Repatha) and alirocumab (Praluent) in several clinically relevant ways.

Dosing frequency is the most obvious distinction. Repatha is dosed every two weeks (140 mg) or monthly (420 mg), and Praluent every two weeks (75 or 150 mg) or every four weeks (300 mg). Leqvio requires three doses in the first year, then two per year thereafter 2. The label specifies healthcare professional administration for Leqvio, whereas both Repatha and Praluent labels permit self-injection at home.

The cardiovascular outcomes evidence base also differs. Repatha's label includes FOURIER trial data (N = 27,564), which showed a 15% reduction in the primary composite endpoint (HR 0.85, 95% CI 0.79-0.92, P<0.001) 9. Praluent's label includes ODYSSEY OUTCOMES data (N = 18,924), showing a 15% reduction in MACE (HR 0.85, 95% CI 0.78-0.93, P = 0.0003) 10. ORION-4 data for Leqvio now provides comparable cardiovascular event evidence, though the specific magnitude of MACE reduction and its comparison to monoclonal antibody PCSK9 inhibitors continue to be analyzed.

All three PCSK9-targeted therapies share injection-site reactions as the most common adverse event. The rate for Leqvio (8.2%) is somewhat higher than reported for Repatha (5.0%) and Praluent (6.1%), though direct comparison across trials is limited by differences in study design and patient populations.

Clinical Implications of Label Changes for Prescribers

For clinicians prescribing Leqvio, the cumulative label changes from 2020 to 2026 carry three practical takeaways.

No hepatic or renal dose adjustments are necessary. The label now clearly states that patients with mild to moderate hepatic impairment and all degrees of renal impairment, including those on hemodialysis, can receive the standard 284 mg dose without modification 7.

Cardiovascular outcomes data now support the LDL-C lowering benefit. ORION-4 results provide prescribers with event-driven evidence to discuss with patients and payers, addressing the primary gap that existed at the time of initial approval 5.

The 2023 American College of Cardiology/AHA Expert Consensus Decision Pathway positions inclisiran as a reasonable option for patients who are not at LDL-C goal despite maximally tolerated statin plus ezetimibe therapy. Prescribers should document statin intolerance or inadequate response before initiating PCSK9-targeted therapy to meet payer prior authorization requirements, regardless of which agent is selected 6.